Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027

Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development

Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD

Strong cash position with operational runway through 2028

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the full year 2025 and provided business highlights.

"2025 marked an important year of execution for SAB. We delivered Phase 1 clinical data for SAB-142, completed a $175 million oversubscribed financing with high quality investors including Sanofi, and advanced SAB-142 into our registrational Phase 2b SAFEGUARD study with the first patient dosed," said Samuel J. Reich, CEO, SAB BIO. "In 2026, our focus is on enrolling SAFEGUARD. We are encouraged by current momentum and remain on track to complete enrollment by year end with topline data expected in the second half of 2027. We also expect to share additional Phase 1 data and support the initiation of an investigator led study as we continue to build the clinical foundation for SAB-142 in T1D."

Recent Pipeline Achievements and Anticipated Milestones for SAB-142

Phase 2b SAFEGUARD Study

   -- Initiated and dosed multiple patients in the SAFEGUARD 
      (SAFety and Efficacy of human anti-thymocyte immunoGlobUlin 
      SAB-142 ARresting progression of type 1 Diabetes) clinical trial of 
      SAB-142 as a novel, potentially best-in-class, disease-modifying 
      immunotherapeutic approach in development to treat T1D by delaying the 
      progression of disease. 
 
   -- Activated multiple clinical trial sites in the U.S., Australia, and New 
      Zealand. 
 
   -- On May 29, 2025, the Company held a constructive Type B meeting with the 
      U.S. Food and Drug Administration (FDA). 
 
          -- The FDA provided guidance leading to alignment on the design and 
             advancement of our Phase 2b SAFEGUARD study. 
 
          -- SAB confirmed its intent with the FDA to utilize the data from the 
             SAFEGUARD study as supportive evidence for future regulatory 
             approval. 
 
   -- Enrollment is ongoing and the Company is on track to complete enrollment 
      in SAFEGUARD by the end of 2026 with topline data expected in 2H 2027. 

Phase 1 Data in Healthy Volunteer, Redosing, and T1D Cohorts

   -- Reported positive confirmatory clinical results from the Phase 1 study of 
      SAB-142 in healthy volunteers, redosing, and T1D cohorts in December 
      2025. 
 
          -- Data confirmed SAB-142 does not cause serum sickness and has 
             low/no immunogenicity at any dose and in all cohorts, including 
             redosed healthy volunteers. 
 
          -- Transient lymphopenia, an on-target marker of target engagement 
             and pharmacodynamic activity, was observed after dosing and 
             rapidly corrected to baseline within 1-3 days in all participants. 
 
          -- The lack of sustained lymphodepletion observed supports the 
             chronic dosing of SAB-142 in an outpatient setting for the 
             treatment of Stage 3 autoimmune type 1 diabetes. 

Business Highlights

   -- David Zaccardelli, Pharm.D., appointed to Board of Directors as Chair in 
      January 2026: Dr. Zaccardelli is an accomplished biopharmaceutical 
      executive with more than 20 years of experience leading companies through 
      transformational growth, including leading companies from clinical to 
      commercial stage. He most recently served as President and Chief 
      Executive Officer of Verona Pharma until its acquisition by Merck & Co. 
 
   -- Rita Jain, M.D., appointed to Board of Directors as Independent Director 
      in January 2026: Dr. Jain is a rheumatologist who brings more than two 
      decades of leadership experience in biopharmaceutical development, 
      clinical strategy, and regulatory affairs across multiple therapeutic 
      areas, including immunology, inflammation, nephrology, and rare diseases. 
 
   -- Completed successful financing raising an upfront $175mm in gross 
      proceeds: In July 2025, SAB BIO raised an upfront $175 million in 
      oversubscribed private placement which included strategic investor Sanofi 
      and top-tier biotech investors, enabling the Company to fully fund the 
      Phase 2b SAFEGUARD study. 
 
          -- In addition, the Company issued milestone-based warrants to 
             purchase up to an aggregate of 1,500,000 shares of the Company's 
             Series B preferred stock, for up to an additional $284 million in 
             gross proceeds if the warrants are exercised in full. 

Upcoming Events

SAB BIO plans to participate in the following investor events and scientific congress:

   -- Leerink Partners Global Biopharma ConferenceDate: March 9, 2026Time: 3:00 
      p.m. ETFormat: Fireside Chat Location: Miami Beach, FL 
 
   -- UBS Biotech Summit Miami, Catalyst for ChangeDate: March 10, 2026Format: 
      1x1 MeetingsLocation: Miami Beach, FL 
   -- Barclays 28th Annual Global Healthcare ConferenceDate: March 11, 
      2026Time: 8:30 a.m. ETFormat: Fireside Chat Location: Miami Beach, FL 
 
   -- 19th International Conference on Advanced Technologies and Treatments for 
      Diabetes (ATTD 2026)Date: March 11-14Location: Barcelona, Spain 

Fiscal Year 2025 Financial Results

   -- Cash Position: Cash, cash equivalents, and available for sale securities 
      of $143.5 million at December 31, 2025, providing operational runway 
      through 2028. 
 
   -- R&D Expenses: Research and development (R&D) expenses of $34.4 
      million and $30.3 million for the years ended December 31, 
      2025, and December 31, 2024, respectively. 
 
   -- G&A Expenses: General and administrative (G&A) expenses of $14.6 
      million and $14.0 million for the years ended December 31, 
      2025, and December 31, 2024, respectively. 
 
   -- Other income: Other income of $62.2 million and $8.8 million for the 
      years ended December 31, 2025, and December 31, 2024, respectively. This 
      increase was driven by the change in fair value of warrant liabilities. 
 
   -- Net income: Net income of $13.3 million and a net loss of $34.1 million 
      for the years ended December 31, 2025, and December 31, 2024, 
      respectively. 

About SAB-142

SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action

analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of "bad acting" T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.

About SAB BIO

SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine$(TM)$, to produce hIgG. SAB BIO's drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency hIgGs that can address a wide range of serious unmet needs in human diseases. The Company's lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.

Forward-Looking Statements

Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "to be," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company's T1D program and other discovery programs, the Company's operational runway, and the future exercise of the Company's outstanding warrants.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry's results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned "Risk Factors" in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Investors:

Cristi Barnett

ir@sab.bio

Media:

Sheila Carlson

media@sab.bio

(END) Dow Jones Newswires

March 09, 2026 17:16 ET (21:16 GMT)